Bull case
Xenon Pharmaceuticals is attractive fundamentally because its lead neuroscience asset, azetukalner, has delivered strong Phase 3 efficacy in drug-resistant focal epilepsy, with 37.6% RR50 at 15mg versus 20.8% for placebo and a 4.8% TEAE discontinuation rate, supporting a differentiated safety-efficacy profile. The company also has meaningful long-term durability data, with 47.3% of 131 patients treated for at least 48 months achieving a six-month seizure-free period, reinforcing the potential for a commercially meaningful, life-changing epilepsy franchise in a large unmet-need population that has often failed five prior ASMs. While psychiatry programs have faced neuropsychiatric safety setbacks and some MDD value has been removed, the core investment case remains strong because epilepsy is still the key value driver, the focal-seizure NDA has been submitted, and the pain pipeline adds additional optionality.